Concepedia

Author

Leah Suttner

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

L. Suttner, L.H. Suttner, Leah H Suttner, Leah H. Suttner, Leah Suttner

45

Publications

254

Citations

9

H-Index

32

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Erasmus MCJohns Hopkins UniversityWayne State UniversitySidney Kimmel Comprehensive Cancer Center
LS

About

Leah Suttner is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and magnetic resonance imaging.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

42

2

Engineering

1

1

10

3

Immunology

1

1

14

4

Neurology

1

1

10

5

Neuroscience

1

1

10

Leah Suttner

×

8

Publications

146

Citations

8

H-Index

YearCitations

No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals

Nicole B. Gabler, Naihua Duan, Eli Raneses,

Trials

2016

39

Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study

Xi Wang, Leah Suttner, Thomas Jemielita,

Journal of Biopharmaceutical Statistics

2021

27

Independent drug action and its statistical implications for development of combination therapies

Cong Chen, Fang Liu, Yixin Ren,

Contemporary Clinical Trials

2020

18

Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).

Emmanuel S. Antonarakis, Jose M. Mateos Rodriguez, Marine Gross‐Goupil,

Journal of Clinical Oncology

2020

14

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors

Anastasios Stathis, Anthony W. Tolcher, Judy S. Wang,

Investigational New Drugs

2023

14

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146

Vicky Makker, Matthew H. Taylor, Carol Aghajanian,

Journal for ImmunoTherapy of Cancer

2024

14

Statistical estimation of white matter microstructure from conventional MRI

Leah Suttner, Amanda F. Mejia, Blake E. Dewey,

NeuroImage Clinical

2016

10

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Julie N. Graff, Christopher Hoimes, Winald R. Gerritsen,

Prostate Cancer and Prostatic Diseases

2024

10

Page 1